Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The Vesalio Neva VS for the Treatment of Symptomatic Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage (aSAH) (The VITAL Study)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- RIA Neurovascular Clinic
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Health System
-
-
Georgia
-
Marietta, Georgia, United States, 30062
- Wellstar Health System
-
-
New York
-
Buffalo, New York, United States, 14204
- University of Buffalo
-
Manhasset, New York, United States, 11030
- North Shore University Hospital - Northwell
-
New York, New York, United States, 10029
- Mount Sinai Health System
-
Stony Brook, New York, United States, 11794
- SUNY Stony Brook University
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37916
- Fort Sanders Regional Med Center
-
-
Texas
-
El Paso, Texas, United States, 79905
- TTUHSC El Paso
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age ≥ 18 years.
- Subarachnoid hemorrhage secondary to ruptured aneurysm.
- Ruptured aneurysm secured with surgical clipping or endovascular intervention.
- Digital subtraction angiography (DSA) or CT angiography at the time of aSAH clinical presentation or aSAH intervention with well-visualized intra-cerebral vessels is available for review.
- Vasospasm in one or more of the following: the internal carotid artery (ICA), basilar, middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) territory on transcranial Doppler (TCD), and/or CT angiography, and/or clinical signs of symptomatic vasospasm (change in level of consciousness, focal neurological deficit) confirmed by > 50% narrowing in these territories on DSA.
- Vasospasm despite maximized medical management defined as oral Nimodipine (unless contraindicated), systemic hypertension with SBP greater than 130 mmHg and euvolemia.
- Target vessel pre-vasospasm diameter ≥ 2 mm and ≤ 4.0 mm.
- Subject or legal representative is able and willing to give informed consent.
Exclusion Criteria
- The presence of an unsecured ruptured aneurysm. Note unsecured unruptured aneurysms remote to the site of treated aSAH are not an exclusionary.
- Symptoms attributable to other causes (e.g., hydrocephalus, metabolic, infection).
- Hunt and Hess Grade of 5
- Large infarct on CT scan defined as ASPECTS 0-5.
- Intracranial hemorrhage not caused by aneurysm rupture.
- History of bleeding disorders.
- Baseline platelets < 30,000.
- International normalized ratio (INR) > 1.7.
- Any known contraindications to mechanical dilation of vasospastic vessels including but not limited to:
- Excessive vessel tortuosity that prevents the placement of the device
- Evidence of rapidly improving neurological signs of stroke
- Large territory completed cerebral infarction, edema with mass effect and intra-parenchymal hemorrhage in vascular territory to be treated, or
- any other vascular anatomic variants or anomalies
- Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
- History of severe allergy to contrast medium.
- Known allergy to NeVa materials (nitinol, stainless steel).
- Suspected or confirmed septic embolus, or bacterial endocarditis.
- Septic shock or central nervous system (CNS) infection confirmed via cerebrospinal fluid (CSF) sampling.
- Known current or recent use of illicit drugs or alcohol abuse.
- Females who are pregnant or breastfeeding.
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure is performed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
NeVa VS
|
mechanical dilatation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedural Success
Time Frame: within 30 minutes of completion of procedure
|
defined as 50% or greater vessel caliber on DSA compared to baseline, as determined by the core laboratory
|
within 30 minutes of completion of procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VS-002 / D
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.